INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 454m ago
HOUSE PTR53m ago
SEC 13F53m ago
ROBINHOOD CHAIN53m ago
CS
Corporate insider

Calvin Sandra

SVP, CHIEF ACCOUNTING OFFICERCIK 0001882909

EDGAR filingsOpen in network
Disclosed transactions29
Buys / sells0 / 7
Max Insider Score32
Connections with evidence1

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
0
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,500 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Travere Therapeutics, Inc.SVP, CHIEF ACCOUNTING OFFICER · Nov 6, 2025
0
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M
$28K
1,250 sh
Sep 15, 2026
Sep 17, 2026
traded Sep 15, 2026
+2d
SEC FORM 4

Evidence

7
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
1,250 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

0
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
1,625 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

2
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$69K
2,500 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

0
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$33K
1,625 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

21
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$266K
4,275 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

14
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$50K
800 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

11
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$19K
300 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

2
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$133K
6,500 sh
Apr 14, 2026Apr 16, 2026
traded Apr 14, 2026
+2dSEC FORM 4

Evidence

30
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$903K
22.0K sh
Apr 14, 2026Apr 16, 2026
traded Apr 14, 2026
+2dSEC FORM 4

Evidence

7
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,500 sh
Apr 14, 2026Apr 16, 2026
traded Apr 14, 2026
+2dSEC FORM 4

Evidence

7
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
6,500 sh
Apr 14, 2026Apr 16, 2026
traded Apr 14, 2026
+2dSEC FORM 4

Evidence

7
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
6,250 sh
Apr 14, 2026Apr 16, 2026
traded Apr 14, 2026
+2dSEC FORM 4

Evidence

2
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$56K
2,500 sh
Apr 14, 2026Apr 16, 2026
traded Apr 14, 2026
+2dSEC FORM 4

Evidence

2
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$56K
6,250 sh
Apr 14, 2026Apr 16, 2026
traded Apr 14, 2026
+2dSEC FORM 4

Evidence

32
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$296K
7,402 sh
Dec 24, 2025Dec 29, 2025
traded Dec 24, 2025
+5dSEC FORM 4

Evidence

23
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$105K
2,910 sh
Dec 15, 2025Dec 16, 2025
traded Dec 15, 2025
+1dSEC FORM 4

Evidence

6
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$56K
6,250 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

9
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$253K
10.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

9
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$413K
15.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

9
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$280K
12.5K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

26
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$2.42M
67.1K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

0
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
10.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

0
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
17.5K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

13
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$470K
17.5K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

0
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
15.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

0
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
12.5K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

11
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
6,250 sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence